Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

This study has been completed.
Xiamen Innovax Biotech Co., Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Information provided by (Responsible Party):
Jun Zhang, Xiamen University Identifier:
First received: December 17, 2010
Last updated: February 20, 2014
Last verified: February 2014